NasdaqGS - Nasdaq Real Time Price USD

Pacira BioSciences, Inc. (PCRX)

Compare
14.54 +0.21 (+1.47%)
At close: September 27 at 4:00 PM EDT
14.83 +0.29 (+1.99%)
After hours: September 27 at 5:02 PM EDT
Loading Chart for PCRX
DELL
  • Previous Close 14.33
  • Open 14.56
  • Bid 14.49 x 300
  • Ask 14.56 x 200
  • Day's Range 14.19 - 14.75
  • 52 Week Range 11.16 - 35.95
  • Volume 621,071
  • Avg. Volume 1,441,830
  • Market Cap (intraday) 670.685M
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) 10.85
  • EPS (TTM) 1.34
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.13

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

www.pacira.com

711

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PCRX

View More

Performance Overview: PCRX

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PCRX
56.91%
S&P 500
20.30%

1-Year Return

PCRX
56.20%
S&P 500
34.27%

3-Year Return

PCRX
74.87%
S&P 500
28.79%

5-Year Return

PCRX
63.51%
S&P 500
92.71%

Compare To: PCRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PCRX

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    670.69M

  • Enterprise Value

    915.05M

  • Trailing P/E

    10.85

  • Forward P/E

    3.75

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.15

  • Price/Book (mrq)

    0.76

  • Enterprise Value/Revenue

    1.33

  • Enterprise Value/EBITDA

    4.92

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.21%

  • Return on Assets (ttm)

    3.96%

  • Return on Equity (ttm)

    7.54%

  • Revenue (ttm)

    690.31M

  • Net Income Avi to Common (ttm)

    63.59M

  • Diluted EPS (ttm)

    1.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    404.23M

  • Total Debt/Equity (mrq)

    73.76%

  • Levered Free Cash Flow (ttm)

    153.5M

Research Analysis: PCRX

View More

Company Insights: PCRX

Research Reports: PCRX

View More

People Also Watch